Founded by Kymab's former leadership team (acquired by Sanofi in 2021)
Quadrucept's QUAD Technology Empowers the Next-Generation of Antibody-based Drugs:-
- Super Antagonists: From new or existing Fab or VHH domains
- Superior “Receptor Bodies”: High avidity receptor-Fc fusion decoy molecules
- Potent Antibody Agonists: Multivalent Fab/VHH receptor clustering
- Improved Target Selectivity: Tetravalent low-affinity high-avidity binding
- Pioneering Bi-Specifics: Flexible formats tailored for every need
- Fc-Multi-valency: Enabling “best-in-class” half-life extension
- “One-Two Punch” ADCs: Avidity-driven targeting-Greater payload capacity
- Simplicity: Highly efficient self-assembly of monomeric building blocks
- Standard Manufacturing: High expression, stability, drug-like properties
- Broad and Early Patent Estate: First to the field – All therapeutic targets
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://quadruceptbio.com
Quadrucept Bio. Ltd. Questions
Quadrucept Bio. Ltd.'s website is http://quadruceptbio.com
Quadrucept Bio. Ltd.'s LinkedIn profile is https://www.linkedin.com/company/quadrucept-bio
Quadrucept Bio. Ltd.'s industry is
Biotechnology Research
Quadrucept Bio. Ltd.'s top competitors are
Quine Biologics, Inc.,
Folium Science,
Renovorx (Nasdaq: Rnxt),
Ollin Biosciences,
Invenra,
Quince Therapeutics,
Nona Biosciences,
Newcells Biotech Ltd,
Snipr Biome - A Crispr Company,
Abwiz Bio Inc.
Quadrucept Bio. Ltd.'s categories are Biotechnology Research
Quadrucept Bio. Ltd.'s founding year is 2016
